Skip to main content

Astrazeneca PLC 6-K, filed Oct 22, 2026

Astrazeneca PLC (AZN)

6-K 2026-10-22 For: 2026-10-22
View Original
Added on October 22, 2026

About this 6-K

Astrazeneca PLC filed this 6-K on October 22, 2026.

AstraZeneca PLC’s Ultomiris received accelerated approval in the US on 22 October 2026 as the first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A nephropathy, showing a 43.4% reduction versus placebo at 34 weeks. AI summary